Lanirapid (Metildigoxin)

Metildigoxin inhibits the Na⁺/K⁺‑ATPase pump on cardiac cells, leading to increased intracellular sodium. This change reduces the activity of the sodium‑calcium exchanger, causing calcium to accumulate inside the cell, which strengthens myocardial contraction and slows atrioventricular nodal conduction.

The appropriate dose of Lanirapid is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, renal function, electrolyte status and response to therapy. No fixed dosing regimen is provided here.

Safety data for Metildigoxin during pregnancy and lactation are limited. It is generally avoided unless the potential benefit outweighs the risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Lanirapid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lanirapid (Metildigoxin) is chemically related to digoxin, the most widely used cardiac glycoside. Both share a similar mechanism of increasing intracellular calcium, but Metildigoxin may have a slightly different pharmacokinetic profile, potentially offering alternative dosing flexibility in certain patient populations.

Lanirapid tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Lanirapid is taken orally, usually with a glass of water. It may be taken with or without food, but consistency with respect to meals is recommended to maintain stable absorption. Patients should follow the prescriber’s instructions regarding timing and any required dose adjustments.

The most serious risks include cardiac arrhythmias such as ventricular tachycardia, severe bradycardia, and visual disturbances like yellow‑green halos. Signs of toxicity—nausea, vomiting, confusion, or visual changes—should prompt immediate medical evaluation.

Lanirapid is contraindicated in patients with known hypersensitivity to Metildigoxin or other cardiac glycosides, those with uncontrolled ventricular arrhythmias, second‑degree or higher AV block without a pacemaker, and patients with severe renal impairment unless dose is carefully adjusted.